Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Ohtuvayre

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment

Quotient’s somatic genomics platform technology will be used to develop the treatment

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

- PMLiVE

Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

- PMLiVE

Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

Weinreich brings clinical development and venture capital experience to the role

- PMLiVE

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Innovative Trials

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links